

INTRABIOTICS PHARMACEUTICALS INC /DE

Form 8-K

June 24, 2004

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 23, 2004**

IntraBiotics Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

| Delaware | 0-29993 | 94-3200380 |
|--|--------------------------|-----------------------------------|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

**2483 East Bayshore Road, Suite 100
Palo Alto, California 94303**

(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(650) 526-6800**

Not Applicable

(Former name or former address, if changed since last report.)

TABLE OF CONTENTS

Item 5. Other Events.

Item 7. Financial Statements and Exhibits.

SIGNATURE

INDEX TO EXHIBITS

EXHIBIT 99.1

Table of Contents

Item 5. Other Events.

On June 23, 2004, IntraBiotics Pharmaceuticals, Inc. announced that it had stopped its iseganan trial in ventilator-associated pneumonia for safety reasons. A copy of the related press release is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.

Item 7. Financial Statements and Exhibits.

(c) Exhibits. The following documents are filed as exhibits to this report:

99.1 Press Release, dated June 23, 2004, entitled IntraBiotics Stopped Isegaran Trial in Ventilator-Associated Pneumonia for Safety Reasons.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**INTRABIOTICS
PHARMACEUTICALS, INC.**

Date: June 24, 2004

/s/ David Tucker
David Tucker
Principal Financial Officer

Table of Contents

INDEX TO EXHIBITS

- 99.1 Press Release, dated June 23, 2004, entitled IntraBiotics Stopped Iseganan Trial in Ventilator-Associated Pneumonia for Safety Reasons.